Salt Lake City, Utah
According to their web site, BioHive works closely with BioUtah to foster community, progress, innovation and transparency as the trusted source for the life science community.
Here are some interesting companies exploring new treatments in SLC.
Recursion Pharmaceutical – Their integrated Recursion Operating System creates a closed-loop system combining proprietary in-house data generation and advanced computational tools to generate novel insights to initiate or accelerate therapeutic programs. They iterate on this approach to create a virtuous cycle of learning within their system and progress programs at each stage of discovery and pre-clinical development.
Their robust pipeline includes candidates for the following disease states:
Cerebral Cavernous Malformation, Neurofibromatosis Type 2,
Clostridioides difficile Colitis, Familial Adenomatous Polyposis,
AXIN1 or APC Mutant Cancers, Cancer Immunotherapy, Target Delta,
HR-Proficient Ovarian Cancer, RBM39,
Cancer Immunotherapy Target Alpha, MYC-Driven Oncology
JSK Therapeutics – JSK Therapeutics (JSKT) was founded in order to develop new anti-cancer therapeutics with fewer side effects.
The lead compound they will bring to market is JS-K, a first-in-class nitric oxide (NO)-generating compound of the arylated diazeniumdiolate class. JS-K was developed through collaboration between the team of Dr. Larry Keefer at the National Cancer Institute (NCI) and Dr. Paul Shami’s laboratory at the University of Utah.
KNOWN Medicine – Has developed the ODIN™ platform, a predictive engine built to understand how any cancer patient will respond to any drug treatment. They have received hundreds of patient samples into their lab and created thousands of organoids from each one. These organoids– the M3DUSA™ models– are dosed with anticancer drugs (chemo-, targeted-, and immuno-therapy) to identify the best treatment course for each cancer and to select the most effective drugs to advance through clinical trials.
Q Therapeutics – Has adopted a unique approach to developing human cell-based therapies for debilitating – and currently incurable – diseases of the brain and spinal cord (the central nervous system, or CNS). Our revolutionary approach focuses on glial cells – non-neuronal cells in the CNS that are essential for supporting, repairing and maintaining normal neuron function and health.
Pyrexer Medical – The global leader in superficial and deep regional hyperthermia systems, developed as an adjunct solution, for the treatment of solid cancer tumors. Pyrexar RF uses non-ionizing radiation to excite surrounding cellular tissue to “fever” temperatures to increase effectiveness when used with radiotherapy.
Halia Therapeutics are discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. They do this by advancing innovative medicines that target the immune system’s response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses.
They have a robust pipeline for NEK7 Inhibitors for gastroenterology, ophthalmology, neuroinflammation, intervertebral disc disease and dermatology. They also have LRRK2 inhibitors for Parkinson’s Disease and Alzheimer’s Disease.